Pharma BD Deal Intelligence
A small $94M UK bolt-on that became the durable engine room of QIAGEN's companion-diagnostics franchise
Full analysis, sources & comparables →GenomeWeb framed the acquisition as QIAGEN 'jumping into personalized medicine,' establishing leadership in companion diagnostics with the most advanced…
Multi-year fallout: QIAGEN and Roche later settled a long-running distribution dispute over DxS's TheraScreen assays, validating how strategically valuable the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
QIAGEN acquired UK companion-diagnostics firm DxS Ltd. for up to approximately $130 million ($95 million upfront plus up to $35 million in milestones), gaining the CE-marked TheraScreen KRAS and EGFR companion-diagnostic menu and associated pharma partnerships.
A small $94M UK bolt-on that became the durable engine room of QIAGEN's companion-diagnostics franchise
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| QIAGEN N.V. / DxS Ltd. (this deal) | 2009 | $130M | 85 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Sigma-Tau Group / Enzon Pharmaceuticals (Specialty Pharma business) | 2009 | $327M | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
← Browse all deals · How we score deals
More: 2009 deals